MedPath

Aggredyne, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:3

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)

Study of AggreGuide A-100 (ADP) Assay

Not Applicable
Completed
Conditions
Platelet Dysfunction Due to Drugs
Risk Factor, Cardiovascular
Interventions
Drug: P2Y12 inhibitor
Device: Platelet function test
First Posted Date
2017-04-12
Last Posted Date
2019-02-21
Lead Sponsor
Aggredyne, Inc.
Target Recruit Count
280
Registration Number
NCT03111420

Aggreguide A-100 ADP Assay Evaluation

Completed
Conditions
ADP Blockers
Platelet Aggregation
First Posted Date
2014-04-14
Last Posted Date
2017-04-04
Lead Sponsor
Aggredyne, Inc.
Target Recruit Count
150
Registration Number
NCT02112539
Locations
🇺🇸

Juno Research, Houston, Texas, United States

AggreGuide 325 mg. Aspirin Study for Aspirin Induced Platelet Dysfunction

Completed
Conditions
Platelet Dysfunction Due to Aspirin Ingestion
First Posted Date
2013-08-02
Last Posted Date
2013-08-02
Lead Sponsor
Aggredyne, Inc.
Target Recruit Count
150
Registration Number
NCT01915407
Locations
🇺🇸

Aggredyne, Inc., Houston, Texas, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath